Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas.
about
Structural insights into PDZ-mediated interaction of NHERF2 and LPA2, a cellular event implicated in CFTR channel regulationDrug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.Microfluidics platform for single-shot dose-response analysis of chloride channel-modulating compoundsModulation of Chloride Channel Functions by the Plant Lignan Compounds Kobusin and Eudesmin.Drug-induced secretory diarrhea: A role for CFTR.Convective washout reduces the antidiarrheal efficacy of enterocyte surface-targeted antisecretory drugsCrofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDSCorneal dystrophy-causing SLC4A11 mutants: suitability for folding-correction therapy.CFTR-NHERF2-LPA₂ Complex in the Airway and Gut Epithelia.Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice.Differential expression of intestinal ion transporters and water channel aquaporins in young piglets challenged with enterotoxigenic Escherichia coli K88.Beyond cystic fibrosis transmembrane conductance regulator (CFTR) single channel kinetics: implications for therapeutic intervention.Personalized Medicine in CF: From Modulator Development to Therapy for Cystic Fibrosis Patients with Rare CFTR Mutations.
P2860
Q27682058-A25F318C-90B6-46C8-B2C3-C74F4E7719A9Q30249747-3D03A1EA-0F9D-45CA-AB6A-86B6513FB79DQ33799668-FD0B1568-2378-4301-AADF-058A05DCDE57Q34888430-93453E80-4892-4FB5-8823-7802A637992BQ36316757-7333E3D2-D329-48A7-B8A5-AEA0EB885A6DQ36385185-83A211C5-16DD-4281-8449-C215C7645E5FQ36568476-9BD01141-4F3A-4B9F-B349-187690B518EEQ37042269-92010885-3DFC-4AC6-905A-2CFF72CAD42BQ38986089-9F92361E-B14A-439E-BDFF-83208E60441EQ41660999-96F7FF31-918C-4D58-AE48-8BE22B956020Q41710343-54B7F955-BBB4-4696-BDB0-50A95CA16B81Q47238445-DC218868-8079-43E7-9105-8BEFAF968A8DQ48235974-63A23EA3-D1FA-4408-AFEA-4736984F657CQ49917915-35E7EC9E-13A3-4394-AC3D-1DD1B7672D72
P2860
Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Recent advances and new perspe ...... n-induced secretory diarrheas.
@en
Recent advances and new perspe ...... n-induced secretory diarrheas.
@nl
type
label
Recent advances and new perspe ...... n-induced secretory diarrheas.
@en
Recent advances and new perspe ...... n-induced secretory diarrheas.
@nl
prefLabel
Recent advances and new perspe ...... n-induced secretory diarrheas.
@en
Recent advances and new perspe ...... n-induced secretory diarrheas.
@nl
P2093
P2860
P356
P1476
Recent advances and new perspe ...... n-induced secretory diarrheas.
@en
P2093
Anjaparavanda P Naren
Naoaki Fujii
Weiqiang Zhang
P2860
P304
P356
10.4155/FMC.12.1
P577
2012-03-01T00:00:00Z